

SHC Community Acquired Pneumonia: ABX Selection Guidelines

Exclusions:

- Hospital associated pneumonia
- Aspiration pneumonia
- Receipt of antibiotics in the last 3 months for any reason (risk for drug resistance – use alternative class)
- Transplant and Oncology patients –coordinate with specialty teams for recommended treatment

Diagnosis: demonstrable infiltrate by chest radiograph or other imaging technique, with or without supporting microbiological data, is required for the diagnosis of pneumonia

Duration of therapy: Guidelines recommend and data supports at least 5 days of therapy with discontinuation of antibiotics when patients are afebrile for ≥ 48 hours and have no more than 1 sign of CAP-associated sign of clinical instability (HR ≤ 100 beats/min; RR ≤ 24 breaths/min; SBP ≥ 90 mm Hg; oxygen saturation $\geq 90\%$)^{1, 4}

Bacterial pneumonia

Outpatient

Empiric regimen
<p>1. Azithromycin 1.5g total dose (500mg x 3 days or 500mg x 1 day, then 250mg x 4 days)</p> <p>Note: Doxycycline monotherapy is not recommended based on 2017 SHC antibiogram data showing >25% doxycycline resistance in <i>S. pneumoniae</i> isolates.</p> <p>If comorbidities[†] or risk factors for drug-resistant <i>S. pneumoniae</i> present:</p> <ol style="list-style-type: none"> 1. Amoxicillin 1g q8h \pm atypical coverage[‡] to complete a 5-7 day course 2. Cefpodoxime 200mg q12h or cefdinir 300mg BID (not SHC formulary) \pm atypical coverage[‡] to complete a 5-7 day course 3. Levofloxacin 750mg q24h (complete 5-7 day course) <p>[†]Comorbidities included in IDSA guidelines: COPD, liver or renal disease, cancer, diabetes, congestive heart failure, alcoholism, asplenia, ABX use in the last 3 months, and immunosuppression</p>

Inpatients, ED (non-ICU)

Initial regimen
<ol style="list-style-type: none"> 1. CTX 1g q24h + azithromycin 500mg PO q24h 2. CTX 1g q24h + doxycycline 100mg PO q12h 3. Levofloxacin 750mg IV/PO q24h (for b-lactam allergy) – Avoid if suspicion of TB <p>Note: it is not necessary to start all CAP patients on IV therapy if they can tolerate oral therapy and are clinically stable</p>
When patient is clinically improving and tolerating PO
<ol style="list-style-type: none"> 1. Amoxicillin 1g q8h \pm atypical coverage[‡] to complete a 5-7 day course 2. Cefpodoxime 200mg q12h or cefdinir 300mg BID (non-formulary at SHC) \pm atypical coverage[‡] to complete a 5-7 day course 3. Levofloxacin 750mg q24h (complete 5-7 day course) <p>[‡]atypical coverage:</p> <ul style="list-style-type: none"> • azithromycin total dose of 1.5 g (500mg x 3 days -OR- 500mg x 1 day then 250-500mg x 4 days) • doxycycline 100mg q12h to complete 5-7 day course <p>Note: ED patients directly discharged to home may use outpatient regimens in outpatient table or the PO regimens in this table.</p>

Viral pneumonia

If influenza present in the community and symptoms compatible with influenza, no testing recommended for outpatients
<ol style="list-style-type: none"> 1. Oseltamivir 75 mg twice daily X 5 days

References:

1. Mandell, Lionel A., et al. "Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults." *CID* 44.Supp 2 (2007): S27-S72.
2. Garin, Nicolas, et al. *JAMA internal medicine* 174.12 (2014): 1894-1901.
3. Postma, Douwe F., et al. *New England Journal of Medicine* 372.14 (2015): 1312-1323.
4. Uranga, Ane et al. Duration of Antibiotic Treatment in Community-Acquired Pneumonia A Multicenter Randomized Clinical Trial *JAMA Intern Med.* 2016;176(9):1257-1265. doi:10.1001/jamainternmed.2016.3633

Document Information:

- A. Original author/date: ASP/SASS team in conjunction with High Value Care 1/2016
- B. Gatekeeper: Antimicrobial Stewardship Program
- C. Review and Renewal Requirement
 - a) This document will be reviewed every three years and as required by change of law or practice
- D. Revision/review history: SASS team 1/16/2018
- E. Approvals
 - a) Antimicrobial Subcommittee: 1/25/2018
 - b) P&T: 2/2018